Results 191 to 200 of about 38,538 (308)

TNMplot: An enhanced platform for pharmacological target identification through cross‐stage and pan‐cancer gene expression analysis

British Journal of Pharmacology, Volume 183, Issue 11, Page 2648-2659, June 2026.
TNMplot.com, a web‐based platform integrating RNA‐Seq and gene‐chip data from 56,938 samples, enables differential gene expression analysis across normal, primary tumour and metastatic tissues, facilitating large‐scale transcriptomic profiling across 22 tumour types.
Áron Bartha, Balázs Győrffy
wiley   +1 more source

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. [PDF]

Front Immunol
Paulsen JS, Slørdahl TS.
europepmc   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 797-805, June 2026.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

Intraperitoneal Co-Delivery of Claudin18.2×41BB and EpCAM×CD3 Bispecific Antibodies via mRNA-LNPs Synergistically Suppresses Gastric Cancer Peritoneal Metastasis Through T Cell Co-Activation. [PDF]

Int J Nanomedicine
Che J, Guo YY, Guo L, Liu J, Li T, Fei Y.   +5 more
europepmc   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections. [PDF]

PLoS Pathog
Bu F, Ye G, Morsheimer K, Turner-Hubbard H, Eaton B, Anantpadma M, Bheemanapally K, Tan C, Davey R, Li F.   +9 more
europepmc   +1 more source

Bone Formation and the Wnt Signaling Pathway. [PDF]

, 2016
Baron, R., Gori, F., Superti-Furga, A.
core   +1 more source

Cutaneous Toxicities Associated With Amivantamab in Patients With Non‐Small Cell Lung Cancer: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Aikaterini Bakella, Antonis Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou   +4 more
wiley   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps. [PDF]

Front Oncol
Shao W, Liu Y, Huang L, Lu S, Zhai Y, Xiong Y, Chen N, Ye P, Lv Q.   +8 more
europepmc   +1 more source